强生

最新新闻

• 评级变动
  RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Raises Target Price to $290
  \u5e02\u573a\u8d44\u8baf · 2026/10/6
• UBS Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $320
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 评级变动
  DBS Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Raises Target Price to $270
  \u5e02\u573a\u8d44\u8baf · 2026/9/12
• BofA Securities Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Raises Target Price to $282
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 评级变动
  TD Cowen Initiates Johnson & Johnson(JNJ.US) With Buy Rating, Announces Target Price $300
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• 评级变动
  Citi Maintains Johnson & Johnson(JNJ.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  Wells Fargo Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $282
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  Scotiabank Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $305
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  Citi Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Raises Target Price to $303
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  UBS Initiates Johnson & Johnson(JNJ.US) With Buy Rating, Announces Target Price $320
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $294
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• Leerink Partners Maintains Johnson & Johnson(JNJ.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• 评级变动
  Guggenheim Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Raises Target Price to $287
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Citi Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Announces Target Price $298
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  BofA Securities Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Raises Target Price to $278
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  Goldman Sachs Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $282
  \u5e02\u573a\u8d44\u8baf · 2026/8/26
• 评级变动
  RBC Capital Initiates Johnson & Johnson(JNJ.US) With Buy Rating, Announces Target Price $287
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• 评级变动
  RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $287
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• 评级变动
  J.P. Morgan Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Raises Target Price to $285
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• Guggenheim Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $287
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  Argus Research Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Raises Target Price to $300
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• 评级变动
  Citi Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $298
  \u5e02\u573a\u8d44\u8baf · 2026/7/23
• UBS Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $320
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 评级变动
  Wells Fargo Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $272
  \u5e02\u573a\u8d44\u8baf · 2026/7/23
• Johnson & Johnson (JNJ.US) seeks priority review in China for talquetotab, a therapy aimed at inhibiting tumor formation and growth.
  Zhitong Finance · 2026/9/24

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。